ICON Public Limited Company ICLR
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +15.99%
- 1 year
- +27.84%
- Open
- 211.52
- Prev close
- 215.48
- Mkt cap
- 15.83B
- Vol
- 2.58M
- Avg vol
- 891.00K
- EPS
- 2.50
- P/E
- 84.54
- Div yield
- 0.00%
More statistics
- Low
- 207.01
- High
- 212.80
- Forward P/E
- 18.24
- Beta
- 1.24
- Short ratio
- 3.06
- Inst. own
- 110.99%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 24, 2027
- 50-d avg
- 171.23
- 200-d avg
- 145.67
- 1y target
- 225.12
2Y chart
Events in this range
- Oct 22, 2025Earnings: 3.31; estimate 3.28; surprise 0.91%
- May 27, 2026Earnings: 2.52; estimate 3.13; surprise -19.49%
- Jun 23, 2026Earnings: 2.5; estimate 2.46; surprise 1.63%
- Jul 29, 2026Earnings: 2.56; estimate 2.55; surprise 0.39%
- Oct 27, 2026Earnings: 2.66; estimate 2.62; surprise 1.53%
- Oct 29, 2026Rating: Truist Securities · Buy → Buy
- Oct 29, 2026Rating: Barclays · Equal-Weight → Equal-Weight
- Oct 29, 2026Rating: UBS · Neutral → Neutral
- Oct 29, 2026Rating: TD Cowen · Buy → Buy
- Oct 29, 2026Rating: Citigroup · Neutral → Neutral
- Oct 29, 2026Rating: RBC Capital · Outperform → Outperform
Signals (98)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 9, 2026 | 3 months ago |
| RSI: Overbought | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 16, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| RSI: Overbought | Jun 3, 2026 | 5 months ago |
| RSI: Overbought | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| RSI: Overbought | May 28, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 30, 2026 | 6 months ago |
| SMA: Bullish | Apr 29, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| MACD: Buy Signal | Feb 27, 2026 | 8 months ago |
| RSI: Oversold | Feb 10, 2026 | 8 months ago |
| RSI: Oversold | Feb 5, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 9 months ago |
| SMA: Bearish | Jan 30, 2026 | 9 months ago |
| SMA: Bullish | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 20, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Jan 6, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 2, 2026 | 10 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 19, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| SMA: Bullish | Nov 25, 2025 | 11 months ago |
| SMA: Bullish | Nov 21, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 21, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 29, 2025 | 1 year ago |
| SMA: Bearish | Oct 28, 2025 | 1 year ago |
| SMA: Bullish | Oct 27, 2025 | 1 year ago |
| SMA: Bearish | Oct 24, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 23, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 21, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 17, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 30, 2025 | 1 year ago |
| SMA: Bullish | Sep 30, 2025 | 1 year ago |
| SMA: Bearish | Sep 23, 2025 | 1 year ago |
| SMA: Bearish | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 16, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Sep 11, 2025 | 1 year ago |
| SMA: Bullish | Sep 11, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| SMA: Bearish | Sep 9, 2025 | 1 year ago |
| SMA: Bullish | Aug 28, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 25, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 4, 2025 | 1 year ago |
| RSI: Overbought | Jul 24, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 23, 2025 | 1 year ago |
| SMA: Bullish | Jul 22, 2025 | 1 year ago |
| SMA: Bearish | Jul 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jun 10, 2025 | 1 year ago |
| MACD: Buy Signal | May 27, 2025 | 1 year ago |
| MACD: Sell Signal | May 21, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 24, 2025 | 1 year ago |
| RSI: Oversold | Apr 17, 2025 | 1 year ago |
| RSI: Oversold | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 20, 2025 | 1 year ago |
| RSI: Oversold | Feb 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 26, 2024 | 1 year ago |
Key statistics
- Market cap
- 15.83B
- Enterprise value
- 18.84B
- Trailing P/E
- 84.54
- Forward P/E
- 18.24
- PEG ratio
- 0.65
- Price / sales
- 1.92
- Price / book
- 1.73
- EPS (TTM)
- 2.50
- Beta
- 1.24
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 5.26%
- Revenue (TTM)
- 8.23B
- Revenue growth
- -2.90%
- Free cash flow
- 538.14M
- Total cash
- 808.98M
- Total debt
- 3.51B
- Return on equity
- 4.70%
- Shares outstanding
- 74.92M
- Short % of float
- 4.50%
- 50-day average
- 171.23
- 200-day average
- 145.67
Analyst view
Consensus: buy
- Target (low)
- 155.00
- Target (mean)
- 225.12
- Target (high)
- 268.00
- Strong buy1
- Buy9
- Hold7
- Sell0
- Strong sell1
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 2.82.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 2.83 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | 2.62 | 2.66 | +0.04 | +1.53% |
| Jul 29, 2026 | Jun 30, 2026 | 2.55 | 2.56 | +0.01 | +0.39% |
| Jun 23, 2026 | Mar 31, 2026 | 2.46 | 2.50 | +0.04 | +1.63% |
| May 27, 2026 | Dec 31, 2025 | 3.13 | 2.52 | -0.61 | -19.49% |
| Oct 22, 2025 | Sep 30, 2025 | 3.28 | 3.31 | +0.03 | +0.91% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 29, 2026 | Citigroup | main | Neutral | Neutral |
| Oct 29, 2026 | TD Cowen | main | Buy | Buy |
| Oct 29, 2026 | UBS | main | Neutral | Neutral |
| Oct 29, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 29, 2026 | Truist Securities | main | Buy | Buy |
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- Ireland
- Website
- iconplc.com
News
- What Icon (ICLR) Said on Its Q3 Earnings Call
- RBC Capital Maintains Outperform on Icon, Raises Price Target to $226
- Citigroup Maintains Neutral on Icon, Raises Price Target to $215
- TD Cowen Maintains Buy on Icon, Raises Price Target to $254
- UBS Maintains Neutral on Icon, Raises Price Target to $236
- Barclays Maintains Equal-Weight on Icon, Raises Price Target to $230
- Truist Securities Maintains Buy on Icon, Raises Price Target to $268
- Baird Maintains Outperform on Icon, Raises Price Target to $249
- ICON Public Limited Company (ICLR) Q3 2026 Earnings Call Transcript
- What Icon (ICLR) Said on Its Q3 Earnings Call
Your note
Sign in to keep a note on ICLR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALFE BARRY EDWARD | Chief Executive Officer | Sale | Aug 9, 2026 | 4,804 |
| CLERKIN NIGEL | Chief Financial Officer | Sale | Aug 10, 2026 | 5,881 |
| CLIMAX JOHN PH.D. | Director | Sale | Aug 10, 2026 | 2,087 |
| GRAIS LINDA SUE M.D. | Director | Sale | Aug 10, 2026 | 6,162 |
| LYONS EMER | Officer | Sale | Oct 22, 2026 | 990 |
| MCCAGUE EUGENE PACELLI | Director | Sale | Aug 10, 2026 | 3,811 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Artisan Partners Limited Partnership | 11.31% | 8,636,406 | 1.83B | Jun 29, 2026 |
| Wellington Management Group, LLP | 6.97% | 5,320,054 | 1.12B | Jun 29, 2026 |
| FMR, LLC | 6.90% | 5,271,321 | 1.11B | Jun 29, 2026 |
| Invesco Ltd. | 6.89% | 5,264,236 | 1.11B | Jun 29, 2026 |
| Harris Associates L.P. | 5.85% | 4,468,146 | 944.39M | Jun 29, 2026 |
| Brave Warrior Advisors, LLC | 4.13% | 3,153,308 | 666.48M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Artisan Partners Funds Inc.-Artisan International Value Fund | 8.83% | 6,744,902 | 1.43B | Jun 29, 2026 |
| HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund | 3.10% | 2,369,000 | 500.71M | Jun 29, 2026 |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 1.37% | 1,042,659 | 220.38M | Jul 30, 2026 |
| Fidelity Puritan Trust-Fidelity Low-Priced Stock Fund | 1.27% | 973,587 | 205.78M | Jul 30, 2026 |
| VANGUARD WINDSOR FUNDS-Vanguard Windsor Fund | 1.24% | 943,171 | 199.35M | Jul 30, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.22% | 933,744 | 197.36M | Jul 30, 2026 |